ConductScience.org, home

Paper18201212

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Vilsbøll T and 10 others. Diabet Med, 2008. Cited by 177 papers, by iCite.

Cite this record

ConductScience Library. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Papers, record 18201212. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18201212

Download JSON
Disease
type 2 diabetes mellitus613 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
PubMed
Journal
Diabet Med
PubMed
Year
2008
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
177
iCite
Relative citation ratio, by iCite
4.62
iCite
Revised in PubMed
2022-04-08
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vilsbøll TT
2Brock BB
3Perrild HH
4Levin KK
5Lervang HHH-H
6Kølendorf KK
7Krarup TT
8Schmitz OO
9Zdravkovic MM
10Le-Thi TT
11Madsbad SS

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Glucagon-Like Peptide 1Major topic
Hypoglycemic AgentsMajor topic
Islets of LangerhansMajor topic
Receptors, GlucagonMajor topic
C-Peptide
Drug Administration Schedule
Female
Humans
Incretins
Insulin Resistance
Liraglutide
Male
Middle Aged
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00154401Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by70

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 177 citations.

PMIDTitleJournalYearIn PapersSource
41440034Metabolic Stress and Adaptation in Pancreatic β-Cells to Hypoxia: Mechanisms, Modulators, and Implications for Transplantation.Cells2025https://conductscience.org/library/papers/41440034PubMed
40869417Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists.Int J Mol Sci2025https://conductscience.org/library/papers/40869417PubMed
40181228How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis.Obes Rev2025https://conductscience.org/library/papers/40181228PubMed
39598383GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39598383PubMed
39044524The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats.J Prev Alzheimers Dis2024https://conductscience.org/library/papers/39044524PubMed
38211595Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.Diabetes Care2024https://conductscience.org/library/papers/38211595PubMed
37707701
Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.
Diabetes Ther2023https://conductscience.org/library/papers/37707701PubMed
37313232Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.touchREV Endocrinol2023https://conductscience.org/library/papers/37313232PubMed
36498669Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.J Clin Med2022https://conductscience.org/library/papers/36498669PubMed
36349778Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.Obes Facts2023https://conductscience.org/library/papers/36349778PubMed
34114119Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function.Handb Exp Pharmacol2022https://conductscience.org/library/papers/34114119PubMed
33626072Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats.PLoS One2021https://conductscience.org/library/papers/33626072PubMed
33473176Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.Int J Obes (Lond)2021https://conductscience.org/library/papers/33473176PubMed
33413317The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.BMC Endocr Disord2021https://conductscience.org/library/papers/33413317PubMed
33190640Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus.BMC Med2020https://conductscience.org/library/papers/33190640PubMed
32348108Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor.ACS Chem Biol2020https://conductscience.org/library/papers/32348108PubMed
31583380The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications.J Obes Metab Syndr2019https://conductscience.org/library/papers/31583380PubMed
31164926Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.Diabetol Metab Syndr2019https://conductscience.org/library/papers/31164926PubMed
31031702The Discovery and Development of Liraglutide and Semaglutide.Front Endocrinol (Lausanne)2019https://conductscience.org/library/papers/31031702PubMed
29895889Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.Sci Rep2018https://conductscience.org/library/papers/29895889PubMed

See all 70 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
LIRAGLUTIDECHEMBL4084119Results1https://conductscience.org/library/drugs/CHEMBL4084119

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18201212

GET https://conductscience.org/api/papers/v1/18201212/cited_by?page=2